Outlook Therapeutics/$OTLK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Outlook Therapeutics
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
- Ticker
- $OTLK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 17
- Headquarters
- Iselin, United States
- Website
- outlooktherapeutics.com
OTLK Metrics
BasicAdvanced
$133M
-
-$0.75
0.75
-
Price and volume
Market cap
$133M
Beta
0.75
52-week high
$2.54
52-week low
$0.16
Average daily volume
4.1M
Financial strength
Current ratio
0.808
Quick ratio
0.449
Long term debt to equity
-0.013
Total debt to equity
-0.938
Interest coverage (TTM)
-210.64%
Profitability
EBITDA (TTM)
-55.532
Gross margin (TTM)
195.61%
Net profit margin (TTM)
5,258.04%
Operating margin (TTM)
4,785.88%
Effective tax rate (TTM)
2.48%
Revenue per employee (TTM)
-$70,000
Management effectiveness
Return on assets (TTM)
-143.17%
Return on equity (TTM)
256.92%
Valuation
Price to revenue (TTM)
-38.274
Price to book
-9.81
Price to tangible book (TTM)
-9.81
Price to free cash flow (TTM)
-0.793
Free cash flow yield (TTM)
-126.10%
Free cash flow per share (TTM)
-0.687
Growth
Revenue change (TTM)
-177.22%
Earnings per share change (TTM)
-50.19%
10-year revenue growth (CAGR)
-8.98%
3-year earnings per share growth (CAGR)
-47.00%
10-year earnings per share growth (CAGR)
-50.22%
What the Analysts think about OTLK
Analyst ratings (Buy, Hold, Sell) for Outlook Therapeutics stock.
Analyst projections of the future price of Outlook Therapeutics stock.
OTLK Financial Performance
Revenues and expenses
OTLK Earnings Performance
Company profitability
Upcoming events
No upcoming events
OTLK News
AllArticlesVideos
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
Business Wire1 month ago
Oncobiologics Q3 Earnings Call Highlights
MarketBeat2 months ago
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.